Harbor Investment Advisory LLC Sells 2,045 Shares of Becton, Dickinson and Company $BDX

Key Points

• Harbor Investment Advisory LLC significantly reduced its holdings in Becton, Dickinson and Company by 73.4%, selling 2,045 shares and retaining only 741 shares worth approximately $128,000.
• Insiders have recently sold a total of 2,965 shares of Becton, Dickinson stock valued at $551,536, indicating a decrease in their ownership stakes.
• Becton, Dickinson and Company reported a quarterly EPS of $3.68, exceeding analysts' expectations and marking a 10.4% revenue growth compared to the previous year.

Harbor Investment Advisory LLC reduced its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 73.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 741 shares of the medical instruments supplier's stock after selling 2,045 shares during the quarter. Harbor Investment Advisory LLC's holdings in Becton, Dickinson and Company were worth $128,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Northcape Wealth Management LLC grew its stake in shares of Becton, Dickinson and Company by 0.5% during the 1st quarter. Northcape Wealth Management LLC now owns 9,814 shares of the medical instruments supplier's stock worth $2,248,000 after acquiring an additional 51 shares in the last quarter. Alpha Omega Wealth Management LLC grew its stake in shares of Becton, Dickinson and Company by 5.7% during the 1st quarter. Alpha Omega Wealth Management LLC now owns 984 shares of the medical instruments supplier's stock worth $225,000 after acquiring an additional 53 shares in the last quarter. Brady Family Wealth LLC grew its stake in shares of Becton, Dickinson and Company by 1.2% during the 1st quarter. Brady Family Wealth LLC now owns 4,317 shares of the medical instruments supplier's stock worth $989,000 after acquiring an additional 53 shares in the last quarter. Diversified Trust Co grew its stake in shares of Becton, Dickinson and Company by 4.7% in the first quarter. Diversified Trust Co now owns 1,188 shares of the medical instruments supplier's stock valued at $272,000 after buying an additional 53 shares in the last quarter. Finally, REAP Financial Group LLC grew its stake in shares of Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after buying an additional 55 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the completion of the sale, the executive vice president owned 4,887 shares of the company's stock, valued at approximately $881,077.23. This trade represents a 19.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director directly owned 22,226 shares of the company's stock, valued at $4,167,375. This represents a 3.96% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 2,965 shares of company stock valued at $551,536 in the last three months. Insiders own 0.36% of the company's stock.

Becton, Dickinson and Company Trading Down 1.8%

BDX stock opened at $187.23 on Monday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62. The company has a fifty day moving average price of $186.46 and a two-hundred day moving average price of $191.26. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The stock has a market cap of $53.66 billion, a price-to-earnings ratio of 33.67, a price-to-earnings-growth ratio of 1.51 and a beta of 0.27.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping analysts' consensus estimates of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.51 billion during the quarter, compared to analysts' expectations of $5.50 billion. During the same period in the previous year, the business posted $3.50 earnings per share. The company's revenue for the quarter was up 10.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. Equities analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 30th. Stockholders of record on Monday, September 8th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.2%. Becton, Dickinson and Company's dividend payout ratio (DPR) is currently 74.82%.

Analyst Ratings Changes

Several equities analysts recently weighed in on BDX shares. Morgan Stanley raised their target price on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Barclays decreased their target price on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a research note on Tuesday, June 3rd. Wells Fargo & Company raised their target price on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the company an "equal weight" rating in a research note on Friday, August 8th. Piper Sandler reissued a "neutral" rating and issued a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Finally, Wall Street Zen raised shares of Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Four analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $211.44.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.